Compare CELU & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CELU | COHN |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.5M | 40.3M |
| IPO Year | N/A | N/A |
| Metric | CELU | COHN |
|---|---|---|
| Price | $1.27 | $17.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 54.7K | ★ 79.0K |
| Earning Date | 11-14-2025 | 03-09-2026 |
| Dividend Yield | N/A | ★ 5.87% |
| EPS Growth | N/A | ★ 6.29 |
| EPS | N/A | ★ 2.50 |
| Revenue | $40,578,000.00 | ★ $185,475,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | ★ N/A | $6.83 |
| Revenue Growth | N/A | ★ 107.11 |
| 52 Week Low | $1.00 | $6.10 |
| 52 Week High | $4.35 | $32.60 |
| Indicator | CELU | COHN |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 45.53 |
| Support Level | $1.25 | $16.81 |
| Resistance Level | $1.32 | $22.29 |
| Average True Range (ATR) | 0.08 | 2.31 |
| MACD | 0.02 | -0.61 |
| Stochastic Oscillator | 34.37 | 7.99 |
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.